Cancer Tumor Profiling Market Overview
Cancer or Tumor Profiling Market was valued at USD 10.8 Billion in 2022 and is projected to grow at a CAGR of 10.1% to reach USD 28.0 Billion by 2032.
Cancer or tumor profiling includes laboratory testing conducted to detect gene mutation, presence of biomarkers or proteins in a tumor tissue sample. Detection of cancer is very important at an early stage before it spreads in the body, thereby making its treatment effective and easy. Increasing number of cancer cases across the globe make it crucial for early and new methods of cancer detection.
Cancer Tumor Profiling Market Drivers & Restraints
|
Drivers |
Restrains |
|
Rising Prevalence of Cancer Cases |
Rise in Immunotherapy |
|
Use of Biomarkers in Cancer Profiling |
Lack of Standard Regulations |
|
High Capita Investment for Biomarker R&D |
Cost Considerations |
|
Preference for Personalized Medicines |
|
Cancer Tumor Profiling Market Segmentations & Regional Insights
Dividing this target market into segments:
Cancer or Tumor Profiling Market is segmented based on Technique, Technology, Application and Region.
Technique Insight
On the basis of Technique, the target market is segmented into Genomics, Proteomics, Metabolomics, and Epigenetics
Technology Insight
On the basis of Technology, the target market is segmented into Sequencing Techniques (NGS, Sanger Sequencing, and Pyro Sequencing), In Situ Hybridization, Immunohistochemistry, qPCR, and Microarray
Application Insight
On the basis of Application, the target market is segmented into Personalized Medicine, Oncological Diagnostics, and Research (Cancer Research and Biomarker Discovery)
Regional Insights:
On region the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
- North America market is estimated to witness a significantly high revenue share over the forecast period due to huge funding available for conducting R&D projects on Cancer/Tumor Profiling and the continuous growth of advanced cancer screening technologies.
- Asia Pacific market is estimated to witness a fastest revenue share over the forecast period due to increase incidences of cancer and wide applications of biomarkers in drug and discovery segment and its adoption.
Cancer or Tumor Profiling Market Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2022 |
|
Forecast period |
2022 – 2032 |
|
Market representation |
Revenue in USD Billion & CAGR from 2022 to 2032 |
|
Market Segmentation |
By Technique – Genomics, Proteomics, Metabolomics, and Epigenetics By Technology - Sequencing Techniques (NGS, Sanger Sequencing, and Pyro Sequencing), In Situ Hybridization, Immunohistochemistry, qPCR, and Microarray By Application - Personalized Medicine, Oncological Diagnostics, and Research (Cancer Research and Biomarker Discovery) |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032.
Cancer Tumor Profiling Market Competitive Landscape & Key Players
The key players operating the cancer or tumor profiling market includes Illumina Inc, QIAGEN, Genomic Health, Inc., NeoGenomics Laboratories, Inc., HTG Molecular Diagnostics, Inc., Caris Life Sciences, Helomics Corp, Oxford Gene Technology IP Limited, Genomic Health, Inc, and NanoString Technologies, Inc.
Cancer Tumor Profiling Market Recent News
- In November 2023, Illumina Inc., a leader in DNA sequencing and array-based technologies, announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available, or to complement tissue-based testing.
- In March 2022, Illumina launched cancer profiling diagnostic in Europe. This is in vitro diagnostic test designed to profile various cancer mutations and help direct patients to targeted therapies. One test eliminates the need for clinicians to run sequential gene assays on multiple tissue biopsy samples.
Cancer Tumor Profiling Market Company Profile
- Illumina Inc.
- Qiagen N.V.
- Thermo Fisher Scientific Inc.
- F-Hoffman-La Roche Ltd.
- Abott Molecular
- Genomic Health Inc.
- NeoGenomics Inc.
- Sysmex Corporation
- Caris Life Sciences
- NanoString Technologies Inc.
Cancer Tumor Profiling Market Highlights
FAQs
The Cancer Tumor Profiling Market is segmented into Cancer Type, Biomarker Type, Technology, Technique, Application and Region.
Cancer Tumor Profiling Market is driven by factors like growing prevalence of cancer diseases and rapid growth in urbanization.
By region, the Cancer Tumor Profiling market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.
The key players operating the Cancer Tumor Profiling Market includes, Illumina Inc., Qiagen N.V., Thermo Fisher Scientific Inc., F-Hoffman-La Roche Ltd., Abbott Molecular, Genomic Health Inc., NeoGenomics Inc., Sysmex Corporation, Caris Life Sciences, NanoString Technologies Inc., and others.
Cancer Tumor Profiling Market accounted for US$ 9.7 billion in 2022 and is estimated to be US$ 31.0 billion by 2032 and is anticipated to register a CAGR of 11.6%.